BioSpace News Archive

Ambrx Biopharma Inc. (NYSE: AMAM ) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close.

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today details for the release of its results for the quarter and year ended December 31, 2022.

Headquartered in London and with operations in Europe and North America, Virtual Science creates cutting-edge software as a service (SaaS) in the life-science and healthcare sectors.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Dicyclomine Hydrochloride Tablets, USP 20 mg.

Bellerophon Therapeutics, Inc. today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock.

Medtronic plc (NYSE: MDT) today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event rates of any prior U.S. FDA Investigational Device Exemption (IDE) trial for atrial fibrillation (AF) ablation or any multi-center PFA study.

Medic Vision, a leading provider of medical imaging solutions and Gateway Diagnostic Imaging, a leading independent imaging provider in North Texas, announced the successful completion of their MRI efficiency improvement project.

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that Siva Therapeutics, Inc. (“Siva”) and its shareholders have waived the requirement for any further equity raise by Sona prior to the closing of the proposed acquisition of Siva by Sona (the “Proposed Transaction”), further to the Company’s announcements dated January 26, February 21 and February 24, 2023.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent family based on International Patent Application PCT/IB2021/022211 (Thermoresponsive Sol-Gels containing cannabinoids), and is taking the International patent application forward in the US, Europe, Canada and Australia.

Aktis Oncology today announced that company management of Aktis Oncology will participate in one-on-one investor meetings at Cowen’s 43rd Annual Healthcare Conference in Boston, MA, on Wednesday, March 8, 2023.